Drug pricing conversations must include the cost of innovation - STAT

Drug pricing conversations must include the cost of innovation - STAT

Drug pricing conversations must take the cost of innovation into consideration

By CRAIG GARTHWAITE AND BENEDIC IPPOLITO

ALEX WONG/GETTY IMAGES

Legislation to lower drug prices may be good for today, but it can undermine incentives to invest in developing tomorrow's innovative products.

READ MORE